News

Alfa Wassermann buys licence
Enlarge image

BusinessItaly

Alfa Wassermann buys licence

05.10.2012 - Italian Alfa Wassermann has acquired an exclusive licence for Theravance’s serotonin 5-HT4 agonist velusetrag.

The US biotech partner can bag up to US$63.5 plus royalties for the exclusive development and commercialisation rights of the treatment for gastrointestinal motility disorders such as constipation, irritable bowel syndrome, functional dyspepsia, and gastroparesis. The Bologna-headquartered pharma firm Alfa Wassermann, will fund Phase II clinical trials and grant Theravance a US$10m option fee payable if Alfa Wassermann exercises its option for Europe, Russia, China,  and other key markets after clinical proof-of-concept. The San Francisco-based biotech firm also is set to receive development, regulatory and sales milestone payments of up to US$53.5m. Additionally it may earn royalties on net sales of velusetrag (TD-5108) up to 20%.

What makes velusetrag so attractive to the Italians is its, up-to-now, beneficial safety profile. Previous treatments for gastrointestinal (GI) dysmotility targeting the 5-hydroxytryptamine(4) receptor, modified the function of the cardiac HERG potassium channel leading to severe adverse effects. Within the Phase II programme, the Italian firm will evaluate the efficacy, safety and tolerability of once-daily oral velusetrag in the treatment of patients with gastroparesis. The disorder has few therapeutic options and it is characterised by delayed gastric emptying in the absence of a mechanical obstruction with symptoms that include early satiety, nausea, vomiting and bloating. Velusetrag has been shown to accelerate gastric emptying in healthy volunteers.

Theravance will retain the full rights to the drug in the US, Canada, Japan and certain other countries. The US firm has completed a 400-patient Phase II proof-of-concept study in chronic idiopathic constipation for the drug. In the trial the compound demonstrated statistically significant prokinetic activity at all three doses (15 mg, 30 mg, and 50 mg) tested.

It was generally well tolerated and showed a low incidence of adverse events at the two lowest doses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/alfa-wasserman-buys-theravance-licence.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%
  • ADDEX3.20 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%

TOP

  • WILEX3.43 EUR75.0%
  • BASILEA122.20 CHF16.9%
  • FORMYCON16.70 EUR16.8%

FLOP

  • SANTHERA94.55 CHF-10.4%
  • STRATEC BIOMEDICAL43.49 EUR-7.5%
  • BIOFRONTERA1.84 EUR-5.6%

TOP

  • SANTHERA94.55 CHF2330.6%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 27.02.2015